U.S. Energy Services Stock News

NasdaqGS:AVAH
NasdaqGS:AVAHHealthcare

Aveanna Uses Family First Deal To Deepen Florida Reach And M&A Path

Aveanna Healthcare Holdings (NasdaqGS:AVAH) announced the acquisition of Family First Homecare. The deal is intended to strengthen Aveanna's position in Florida and widen its geographic reach. The company also outlined a transformation that increased preferred payer agreements and set new M&A priorities for 2026. Aveanna Healthcare focuses on home based care services, an area many investors watch as care delivery shifts closer to the home. By adding Family First Homecare, the company is...
NasdaqGS:SATS
NasdaqGS:SATSMedia

Is It Too Late To Consider EchoStar (SATS) After A 315% One Year Surge?

Investors may be wondering if EchoStar at around US$109.84 is still offering value after its substantial rise, or if most of the easier gains are already behind it. The stock has delivered a 315.1% return over the last year, even with a 4.4% decline over the past month and a 2.1% decline year to date. This can change how the market views its risk and reward trade off. Recent coverage has focused on EchoStar's sharp multi year share price gains and what that means for current holders and new...
NYSE:CW
NYSE:CWAerospace & Defense

Assessing Curtiss-Wright (CW) Valuation As Middle East Tensions Drive Energy Costs And Pressure Industrials

Geopolitical tensions in the Middle East, along with the related jump in energy prices, have put industrial stocks in focus again, with Curtiss-Wright (CW) drawing attention as investors reassess cost pressures and economic sensitivities. See our latest analysis for Curtiss-Wright. Curtiss-Wright’s share price has been volatile around geopolitical headlines, with a 1-day share price return of a 2.95% decline, a 90-day share price return of 20.96%, and a 1-year total shareholder return of...
NYSE:EPAC
NYSE:EPACMachinery

Is Enerpac Tool Group (EPAC) Offering Value After Recent Share Price Weakness?

If you are wondering whether Enerpac Tool Group at around US$35.97 is a bargain, fairly priced, or looking stretched, this article walks through the key valuation angles to help you frame that question clearly. The stock is roughly flat over the last week with a 0.3% return. That sits against a 14.7% decline over the last month and a 14.8% decline over the last year, even as the 3 year and 5 year returns are 37.7% and 38.0% respectively. Recent coverage has focused on how Enerpac Tool Group...
NasdaqGM:FMBH
NasdaqGM:FMBHBanks

Is It Time To Reassess First Mid Bancshares (FMBH) After Recent Share Price Weakness?

Wondering if First Mid Bancshares at around US$39.44 is giving you fair value or a potential bargain? This article breaks down what the current price might be implying about the business. The stock is roughly flat over the last week at 0.1%, has seen a 9.2% decline over the past month, yet is still up 2.1% year to date and 15.5% over the last year, with a 59.7% return across three years and 0.4% over five years. Recent coverage around regional banks has focused on how share prices react to...
NasdaqGM:RZLV
NasdaqGM:RZLVSoftware

Is It Time To Reassess Rezolve AI (RZLV) After Its Recent Share Price Swings?

Wondering if Rezolve AI at US$2.53 is still priced for a turnaround or already baking in the story? This breakdown will help you frame what the current market price may be implying. The stock has been volatile recently, with a 5.9% decline over the last week, a 13.5% gain over the last month, an 11.8% year to date drop, and a 53.3% return over the past year, all set against a 74.9% decline over three years. Recent coverage has focused on Rezolve AI as an emerging player in the listed AI...
NasdaqGS:PLMR
NasdaqGS:PLMRInsurance

What Palomar Holdings (PLMR)'s Revenue Beat in Catastrophe Insurance Means For Shareholders

In its latest quarterly report, Palomar Holdings, a specialty insurer focused on catastrophe markets such as earthquake coverage, delivered revenue that exceeded analyst expectations. This stronger-than-expected top line performance has drawn renewed market attention to how Palomar’s catastrophe-focused business model is responding to current insurance demand trends. With revenue surpassing analyst forecasts, we’ll now examine how this earnings surprise may influence Palomar’s investment...
NasdaqGS:ALGN
NasdaqGS:ALGNMedical Equipment

A Look At Align Technology (ALGN) Valuation As Elliott Investment Management Takes A Major Stake

Elliott Investment Management has quietly become one of the largest shareholders in Align Technology (ALGN), preparing to engage management on options to improve stock performance, a development that has quickly drawn investor attention. See our latest analysis for Align Technology. At a share price of US$173.18, Align has seen a 5.45% 7 day share price return and a 9.82% 90 day share price return. The 3 year total shareholder return of a 43.53% decline indicates that longer term momentum has...
NasdaqGS:ZBRA
NasdaqGS:ZBRAElectronic

PC Connection Award Highlights Zebra Partner Model And Valuation Gap

PC Connection has been named Zebra Technologies' 2025 Partner of the Year for National Solutions Providers. The award recognizes PC Connection's role in expanding Zebra's solutions and services across its channel network. This partnership focus centers on Zebra Technologies (NasdaqGS:ZBRA), a supplier of data capture, automation, and enterprise technology. Zebra Technologies, traded as NasdaqGS:ZBRA, sells hardware, software, and services that support barcode scanning, RFID, mobile...
NYSE:RYN
NYSE:RYNSpecialized REITs

How Investors Are Reacting To Rayonier (RYN) Leadership Shake‑Up In Wood Products Post‑Merger Integration

Rayonier has announced that Ashlee Townsend Cribb resigned earlier this month as Executive Vice President, Wood Products, effective March 20, 2026, with veteran operations leader Ryan M. Daniels stepping in as Interim Senior Vice President while the company conducts a broader search. This leadership change places a long-tenured wood products operator at the helm during an important period for integrating the recently merged wood products platform and managing operational execution. Next,...
NasdaqGM:ACMR
NasdaqGM:ACMRSemiconductor

Is It Time To Reassess ACM Research (ACMR) After Its Recent Share Price Pullback?

If you are wondering whether ACM Research at around US$43.55 is still attractively priced after its recent run, this article walks through what the current market price may be implying about the stock. The share price has seen a 6.1% decline over the past week and a 32.6% decline over the past month, while still sitting on a 62.1% return over the last year and a very large 3 year gain alongside a 56.7% return over 5 years, which can change how investors think about both upside and...
NasdaqGM:GPCR
NasdaqGM:GPCRPharmaceuticals

Assessing Structure Therapeutics (GPCR) Valuation After Recent Share Price Volatility

Structure Therapeutics (GPCR) has drawn investor attention after recent share price volatility, with the stock closing at US$48.59 and showing sizable moves over the past month and over the past three months. See our latest analysis for Structure Therapeutics. Those recent share price moves come after a sharp pullback. The 30 day share price return shows a 28.92% decline and the 90 day share price return shows a 25.18% decline, while the 1 year total shareholder return remains very large at...
NYSE:WAL
NYSE:WALBanks

Western Alliance Bank’s Veterans Dental Push And What It Means For WAL

Western Alliance Bank, part of Western Alliance Bancorporation (NYSE:WAL), has launched a new veterans dental care initiative in Phoenix. The bank is providing a $100,000 charitable donation to help create a dedicated dental program for veterans experiencing housing insecurity. This initiative is intended as a permanent, targeted support program focused on a vulnerable local population. For investors watching Western Alliance Bancorporation at a share price of $67.04, this new veterans...
OTCPK:SWDR
OTCPK:SWDRREITs

Starwood Real Estate Income Trust (OTCPK:SWDR) FFO Loss Rekindles Dividend Sustainability Debate

Starwood Real Estate Income Trust (OTCPK:SWDR) has posted its FY 2025 numbers with fourth quarter revenue of US$402.8 million, a basic EPS loss of US$0.39, and funds from operations of US$4.4 million in the red, setting the tone for a year where trailing twelve month revenue reached about US$1.6 billion alongside a net loss of US$691.6 million. Over recent quarters, revenue has moved in a tight band between US$389.7 million and US$420.2 million while EPS has remained in loss territory. As a...
NasdaqGS:CRWV
NasdaqGS:CRWVIT

Is It Time To Reassess CoreWeave (CRWV) After Recent AI Infrastructure Headlines?

If you are wondering whether CoreWeave at around US$81.47 offers fair value or a potential opportunity, this article will help you frame that question clearly before you commit fresh capital. The stock is roughly flat over the past week with a 0.4% return, while the 30 day return of a 14.6% decline and the year to date gain of 2.7% indicate that sentiment has shifted recently. Recent headlines have focused on CoreWeave as part of broader discussions about AI infrastructure and cloud related...
NYSE:TFX
NYSE:TFXMedical Equipment

Is It Time To Reassess Teleflex (TFX) After A Multi Year Share Price Slump

If you have been wondering whether Teleflex at around US$105.41 is pricing in too much risk or leaving room for upside, you are not alone. The stock has seen a 1.8% decline over the past week, a 6.3% decline over the last month, and is down 13.9% year to date, with a 24.7% decline over the past year and a 56.6% decline over three years, extending to a 73.6% decline over five years. These moves have put Teleflex firmly on the radar for investors who focus on medical equipment names that have...
NasdaqGS:BANR
NasdaqGS:BANRBanks

Assessing Banner (BANR) Valuation After Recent Share Price Pullback And 17.5% Discount Signal

Why Banner Stock Is Drawing Attention Now Banner (BANR) is back on investor radars after recent share price pressure, including a return of about a 9% decline over the past month and roughly a 12% decline over the past 3 months. See our latest analysis for Banner. At a share price of US$58.07, Banner’s recent 1 month share price return of a 9.24% decline and year to date share price return of a 7.04% decline contrast with its 3 year total shareholder return of 18.77%. This suggests recent...
NYSE:VMC
NYSE:VMCBasic Materials

Is Vulcan Materials (VMC) Now At An Attractive Price After Recent Share Pullback?

Wondering if Vulcan Materials at US$258.40 is priced for opportunity or already expensive? This breakdown focuses squarely on what you are getting for the price you pay. The stock has seen a 2.6% decline over the last 7 days and a 13.7% decline over the last 30 days, even though the 1 year return sits at 11.2% and the 3 year return at 59.0%. Recent coverage has highlighted Vulcan Materials as a key U.S. construction materials supplier, with investors watching how infrastructure spending and...
NYSE:YSS
NYSE:YSSAerospace & Defense

York Space Systems (YSS) Is Up 6.4% After Backlog-Backed 2026 Revenue Outlook and Loss Narrowing

York Space Systems recently reported full-year 2025 results, with sales rising to US$386.2 million while net loss narrowed to US$84.54 million, and issued 2026 revenue guidance of US$545 million to US$595 million, mostly backed by existing backlog. The company also highlighted that over 70% of its 2026 revenue target at the midpoint is already supported by contracted backlog, while recent acquisitions such as Orbion Space Technology and ATLAS Space Operations aim to strengthen its vertically...
NasdaqGS:FIVE
NasdaqGS:FIVESpecialty Retail

Is It Too Late To Consider Buying Five Below (FIVE) After A 198% One Year Rally?

Wondering if Five Below at around US$227 is still a worthwhile idea or if the value has already been priced in? This article is built to help you frame that question clearly. The stock last closed at US$227.42, with returns of 8.1% over 7 days, 6.1% over 30 days, 17.6% year to date and 198.3% over 1 year. Those figures naturally raise questions about how much upside or risk may now be on the table. Recent coverage has focused on Five Below as a fast growing specialty retailer in the US...
NYSE:IDT
NYSE:IDTTelecom

How Dividend Hike and Earnings Beat At IDT (IDT) Has Changed Its Investment Story

IDT Corporation recently reported past second-quarter fiscal 2026 results showing higher sales and net income year-over-year, alongside improved earnings per share from continuing operations. The board also raised the annual dividend from US$0.24 to US$0.28 per share, signaling confidence in the company’s cash generation and capital return plans. With this dividend increase as a starting point, we’ll now examine how these developments could influence IDT’s broader investment narrative. AI is...
NasdaqCM:EXAS
NasdaqCM:EXASBiotechs

The Bull Case For Exact Sciences (EXAS) Could Change Following Walgreens’ Nationwide Cologuard Pharmacy Rollout

In March 2026, Walgreens announced a nationwide initiative with Exact Sciences and Workflow Services that lets eligible, average-risk customers request the FDA-approved, at-home Cologuard colorectal cancer screening test through its pharmacies, aiming to close care gaps with pharmacist-led services integrated into store workflows. At the same time, Exact Sciences highlighted new data on its Oncodetect molecular residual disease test and Cancerguard multi-cancer early detection assay at the...
NasdaqGS:HQY
NasdaqGS:HQYHealthcare

Is It Time To Reconsider HealthEquity (HQY) After Recent Share Price Weakness

If you are wondering whether HealthEquity is attractively priced or if the opportunity has already passed, this article walks through the key numbers that matter for valuation. The stock last closed at US$81.02, with returns of 4.1% over 7 days and 5.1% over 30 days. Year to date the return stands at an 11.0% decline and the 1-year return is a 4.5% decline, compared with a 44.6% gain over 3 years and 15.7% over 5 years. Recent headlines around HealthEquity have focused on its position in...
NasdaqGS:TSHA
NasdaqGS:TSHABiotechs

Taysha Gene Therapies Advances Rett Program As Valuation Draws Investor Focus

Taysha Gene Therapies (NasdaqGS:TSHA) received FDA Breakthrough Therapy designation for TSHA-102 in Rett syndrome. The company reported a 100% patient response rate in pivotal Phase I/II data for TSHA-102. Regulators aligned with Taysha on pivotal trial designs for its lead Rett syndrome program. Taysha added a key commercial hire as it prepares for potential TSHA-102 commercialization. Taysha Gene Therapies, trading at $4.4 per share, has been drawing attention as its 1 year return stands...